Why do standard medical trials often exclude older adults with multimorbidity?

✓ Accepted answer

Standard medical trials often exclude older adults with multimorbidity because researchers prioritize statistical clarity and safety, needing to isolate the specific effects of a new treatment without the confounding variables that multiple simultaneous chronic diseases introduce.

• Confounding Variables: In clinical research, "clean" data is essential to determine if a drug works. When a participant has heart disease, diabetes, and arthritis simultaneously, it becomes nearly impossible to attribute a change in health outcome specifically to the new medication rather than the progression of one of their underlying conditions. This ambiguity can dilute results or obscure safety signals.
• Medication Interactions: As noted by experts at Johns Hopkins University, such as Drs. Cynthia Boyd and Matthew McNabney, managing multiple conditions is complex because medicines frequently interact. Adding a trial drug to a patient already taking numerous medications creates a higher risk of adverse drug interactions, making enrollment ethically complex for trial designers who must minimize participant risk.
• Statistical Power: Trials often require a specific sample size to detect a treatment effect. Excluding patients with too many comorbidities simplifies the recruitment pool, allowing researchers to achieve statistical power more quickly than if they had to account for the wide variance in health statuses typical of the general senior population.
• Demographic Reality Gap: According to the American Geriatrics Society, approximately 50% of adults aged 65 and older have three or more chronic health problems. By excluding these individuals, trial results may not reflect the real-world efficacy or safety profile for the majority of seniors who will actually use these drugs.
• Regulatory Expectations: The US FDA and UK Medicines and Healthcare products Regulatory Agency (MHRA) expect sponsors to demonstrate that a drug’s risks are manageable. Sponsors often restrict entry to patients with stable, single-condition profiles to reduce liability and streamline the approval process, though this is increasingly under scrutiny for lacking inclusivity.

admin · 2026-10-11 16:06:13